Corvus Pharmaceuticals Inc

Gesloten

15.21 -0.26

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

15.14

Max

15.63

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-14M

EPS

-0.15

Werknemers

37

EBITDA

312K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+107.49% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-199M

1.1B

Vorige openingsprijs

15.47

Vorige sluitingsprijs

15.21

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jul 2026, 23:51 UTC

Bitcoin and Ethereum rise as weak U.S. jobs data dims Fed rate hike expectations, while Asian markets react positively to easing geopolitical tensions.

5 jul 2026, 23:51 UTC

Bitcoin and Ethereum see positive returns amid weak U.S. jobs data and stable Eurozone activity, while geopolitical tensions ease.

5 jul 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. jobs data dims Fed rate hike expectations ahead of key FOMC minutes release.

5 jul 2026, 23:51 UTC

Disappointing U.S. jobs report dampens interest rate hike expectations, impacting investor sentiment and market stability ahead of key economic releases.

5 jul 2026, 23:51 UTC

ISM Services PMI Forecasted at 54.2 Indicates Continued Growth Amid Economic Uncertainties and Potential Fed Policy Shifts

5 jul 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Sunday’s session, continuing its upward trajectory since Saturday's close. The asset remains above its 20-day moving average.

5 jul 2026, 23:41 UTC

Canada's Full-Time Employment Change Data Release on July 10 Sparks Market Focus Amid Economic Uncertainty and Government Initiatives.

5 jul 2026, 23:41 UTC

Canada's Part-Time Employment Change Data Release on July 10, 2026, Could Signal Economic Health Amid Government Policy Announcements.

5 jul 2026, 23:41 UTC

Canada's unemployment rate data release on July 10, 2026, expected to show slight improvement at 6.6%, amid mixed signals in job growth and inflation concerns impacting monetary policy.

5 jul 2026, 23:41 UTC

Canada's Employment Change Report Forecasts 10,000 Job Increase Amid Mixed Market Sentiment and Economic Challenges

5 jul 2026, 23:41 UTC

Canada's Labor Force Participation Rate Release Amid Growing Concerns Over Job Security Due to AI and Automation

5 jul 2026, 23:31 UTC

Macro News
Correlated Moves

Silver prices are rising, supported by a recovery in gold and recent oil supply increases. The U.S. dollar's strength may limit upward momentum.

5 jul 2026, 23:31 UTC

Correlated Moves

XRP is trading roughly flat amid broader market sentiment, with Bitcoin moving moderately. The cumulative price change since Saturday remains minimal.

5 jul 2026, 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Strong Performance Amid Trade Tensions and Inflationary Pressures

5 jul 2026, 23:22 UTC

U.S. Balance of Trade report on July 7 forecasts a $78.8 billion deficit, raising concerns over persistent trade imbalances and potential impacts on monetary policy amid cautious market sentiment.

5 jul 2026, 23:22 UTC

U.S. Imports Data Release on July 7 Expected to Show Continued Growth Amid Tariff Impacts and Supply Chain Adjustments

5 jul 2026, 23:22 UTC

Brazil's July 10 inflation rate release draws market attention amid global economic concerns and potential volatility.

5 jul 2026, 23:22 UTC

Mexico's July Inflation Rate Release Expected to Show Stabilization Around 3.94%, Influencing Future Banxico Policy Decisions

5 jul 2026, 23:22 UTC

Brazil's June Inflation Rate Expected to Rise, Heightening Market Volatility Ahead of July 10 Release

5 jul 2026, 23:22 UTC

Mexico's June Inflation Rate Release on July 9 Expected to Influence Monetary Policy Amid Global Economic Concerns.

5 jul 2026, 23:22 UTC

Canada's Balance of Trade data set for July 7, 2026, anticipates a C$2.4 billion surplus amid strong export activity and cautious optimism despite global uncertainties.

5 jul 2026, 23:11 UTC

USD/HKD is trading roughly flat after-market, with no specific news identified. Anticipation surrounds upcoming FOMC minutes and inflation data.

5 jul 2026, 23:02 UTC

Macro News
Correlated Moves

The U.S. dollar has recovered against the Canadian dollar, leading to a slight gain in USD/CAD after-market trading.

5 jul 2026, 23:02 UTC

Gold and silver are trading lower during Sunday’s session, continuing a downward trend since Friday's close. Market participants await key economic data.

5 jul 2026, 23:01 UTC

Correlated Moves

Silver/AUD is trading higher, supported by gold's gains and reduced interest rate hike expectations following weaker job growth data.

5 jul 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and market volatility ahead of key economic data releases.

5 jul 2026, 23:01 UTC

Correlated Moves

Silver/GBP is trading higher, reflecting gains in gold prices. The recent trend includes four consecutive sessions of closing higher.

5 jul 2026, 23:01 UTC

Correlated Moves

Silver/CHF is trading higher, reflecting gains from correlated movements in gold. The upward trend continues after four consecutive sessions of increases.

5 jul 2026, 23:01 UTC

Correlated Moves

Gold/HKD is higher, supported by positive market sentiment and a rise in silver. Weaker job growth data has reduced expectations for immediate interest rate hikes.

5 jul 2026, 23:01 UTC

Correlated Moves

Silver/CAD is higher, reflecting gains alongside rising gold prices. The asset has seen four consecutive sessions of higher closes amid significant volatility.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

107.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD  107.49%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat